Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles in clinical settings
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that […]
















